Research map: Gastrointestinal Motility Effects of GLP-1 Receptor Agonists

Back to the article

Papers in this map

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  2. Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review · Julien Ognard · 2025 · 5 citations · Cites this paper
  3. Small Bowel Bleeding Due to Vascular Lesions: Pathogenesis and Management · 2025 · Related
  4. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial · Hertzel C. Gerstein · 2019 · 3179 citations · Cited by this paper
  5. Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes · Ashwin A. Pillai · 2025 · 3 citations · Cites this paper
  6. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial · Adrian F. Hernandez · 2018 · 1848 citations · Cited by this paper
  7. What obgyns need to know about GLP-1 receptor agonists · Ipsita Chauhan · 2026 · 1 citation · Cites this paper
  8. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  9. Preoperative management algorithm for endoscopic or surgical interventions in patients receiving incretin mimetics · В. В. Салухов · 2026 · 1 citation · Cites this paper
  10. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · Ania M. Jastreboff · 2023 · 1110 citations · Cited by this paper
  11. Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet · Takahiro Hiraide · 2025 · 1 citation · Cites this paper
  12. The Microbiota-Gut-Brain Axis: From Motility to Mood · Kara Gross Margolis · 2021 · 1009 citations · Cited by this paper
  13. Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers · Zhe Li · 2026 · 1 citation · Cites this paper
  14. Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation · Lotte Bjerre Knudsen · 2010 · 663 citations · Cited by this paper
  15. Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation · Tahmid Hussain · 2026 · 1 citation · Cites this paper
  16. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity · Sean Wharton · 2023 · 464 citations · Cited by this paper
  17. Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model · Jens Bjelke Kristensen · 2026 · Cites this paper
  18. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity · Martin Haljeta Friedrichsen · 2020 · 416 citations · Cited by this paper
  19. Preoperative fasting and GLP-1 receptor agonists: gastric retention without increased aspiration risk · Filomena Di Vezza · 2025 · Cites this paper
  20. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases · Liyun He · 2022 · 344 citations · Cited by this paper
  21. Rapport 26-08. Les agonistes des récepteurs aux incrétines dans le traitement de l’obésité : Entre efficacité clinique, éthique et économie de la santé · Charles‐Henri Malbert · 2026 · Cites this paper
  22. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity · Eduardo L. Grunvald · 2022 · 342 citations · Cited by this paper
  23. Acute ischaemic colitis after initiation of tirzepatide in an elderly patient with type 2 diabetes · Gianluigi Cuomo · 2026 · Cites this paper
  24. Mapping the effectiveness and risks of GLP-1 receptor agonists · Yan Xie · 2025 · 289 citations · Cited by this paper
  25. Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study · Fadi Abu Baker · 2026 · Cites this paper
  26. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies · Lin Wang · 2019 · 250 citations · Cited by this paper
  27. Orofacial adverse events associated with Glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study · Stella O. Oyewole · 2026 · Cites this paper
  28. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database · Lulu Liu · 2022 · 246 citations · Cited by this paper
  29. Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery · Guy Nguefang · 2026 · Cites this paper
  30. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024 · Nuha A. ElSayed · 2023 · 206 citations · Cited by this paper
  31. The development of a mindful eating app for adolescents through mixed-methods feedback from adolescents with overweight or obesity · Monica Serrano Gonzalez · 2025 · Cites this paper
  32. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis · Xinda Chen · 2023 · 182 citations · Cited by this paper
  33. Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors · Chen-Xi Deng · 2026 · Cites this paper
  34. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy · Edy Kornelius · 2024 · 132 citations · Cited by this paper
  35. Perioperative anesthesia and aspiration-related outcomes in patients receiving GLP-1 receptor agonists undergoing urgent and elective procedures: a systematic review · Emre Adalier · 2026 · Cites this paper
  36. Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes · Lindsey Wang · 2024 · 130 citations · Cited by this paper
  37. Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin‐based therapies · Ilaria Serra · 2026 · Cites this paper
  38. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice · Mette Simone Aae Madsen · 2019 · 120 citations · Cited by this paper
  39. Excessively low energy intake during obesity treatment with incretin analogs: clinical risks and management in primary care · Erika Čermáková · 2026 · Cites this paper

Source: OpenAlex (CC0)